Interleukin 4 or Cytokine Antagonists? Time to Change the Search for Novel Psoriasis Therapies

Publisher： Karger

E-ISSN： 1421-9832|221|1|27-29

ISSN： 1018-8665

Source： Dermatology, Vol.221, Iss.1, 2010-06, pp. : 27-29

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Interleukin 12 and Psoriasis

By  

Dermatology, Vol. 199, Iss. 2, 1999-10 ,pp. : 101-101

Karger

Access to resources Recommend Favorite

Recombinant Murine Interleukin 4 Protein Therapy for Psoriasis in a Transgenic VEGF Mouse Model

By  

Dermatology, Vol. 219, Iss. 3, 2009-08 ,pp. : 232-238

Karger

Access to resources Recommend Favorite

Circulating CD4+CD25brightFOXP3+ T Cells Are Up-Regulated by Biological Therapies and Correlate with the Clinical Response in Psoriasis Patients

By  

Dermatology, Vol. 219, Iss. 3, 2009-09 ,pp. : 250-258

Karger

Access to resources Recommend Favorite

Eosinophilia during Psoriasis Treatment with TNF Antagonists

By  

Dermatology, Vol. 223, Iss. 4, 2012-02 ,pp. : 311-315

Karger

Access to resources Recommend Favorite

Switching Biologicals: Switching TNFα Antagonists in Psoriasis Treatment

By  

Dermatology, Vol. 216, Iss. 4, 2008-01 ,pp. : 281-282

Karger

Access to resources Recommend Favorite